| Drug advisors focus on ecstasy | Posted on 29/09/2008 in Industry related health news A reclassification of the drug ecstasy is being discussed by the government's independent advisors on the issue today.
The Advisory Council on the Misuse of Drugs (ACMD) will spend the day hearing evidence and putting questions to expert speakers on ecstasy, which is currently a class A drug.
Presentations on trends in its use, its neuropsychological effects, mortality data and neuroimaging will all feature in the session before ACMD members meet in private to discuss their recommendations.
A spokesperson for the council told politics.co.uk the review was underway after a request from the Commons' science and technology committee, rather than the government.
And the Home Office remains vehemently opposed to any change from ecstasy's current classification as a class A drug.
"Ecstasy can and does kill unpredictably; there is no such thing as a 'safe dose'," a Home Office spokesperson said.
Today's review will provide recommendations on "social misuse and harms" rather than the legal punishment for each drug, a major change introduced after a 2006 report from the Commons select committee.
The ACMD is scheduled to submit its recommendations to ministers in early 2009. Other news stories from 29/09/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
